We met Jan Hedner, of Gothenburg, Sweden, at ERS 2019, who talks us through the latest evidence for the effectiveness of carbon anhydrase inhibitors for treatment of obstructive sleep apnoea.
Questions
1. What are the limitations of continuous positive airway pressure (CPAP) in the treatment of obstructive sleep apnoea (OSA)? (0:05)
2. What properties of carbonic anhydrase inhibitors explain their effectiveness in OSA? (0:51)
3. What carbonic anhydrase inhibitors are used in the treatment of OSA? (1:45)
4. What clinical evidence supports their use? (2:36)
5. Which OSA patients are most likely to respond to carbonic anhydrase inhibitors? (3:17)
Speaker disclosures: Jan Hedner has nothing to disclose in relation to this video interview.
touchRESPIRATORY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Filmed at the European Respiratory Society (ERS) International Congress 2019, Madrid, Spain.
